1 / 23

Menopause

Max Brinsmead PhD FRANZCOG February 2011. Menopause. Definition. Menopause is technically a woman’s last menstrual period That is the end of potential reproductive life when follicular activity in the ovaries cease and oestrogen levels fall

buzz
Download Presentation

Menopause

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Max Brinsmead PhD FRANZCOG February 2011 Menopause

  2. Definition • Menopause is technically a woman’s last menstrual period • That is the end of potential reproductive life when follicular activity in the ovaries cease and oestrogen levels fall • Often preceded by several years of erratic cycling. This is called the climacteric... • A rather confusing term • For practical purposes a woman is said to be post menopausal when she has not had a menstrual period for 12 months (and other causes of secondary amenorrhoea have been excluded)

  3. Diagnosis • Essentially a diagnosis in retrospect • Is best made on clinical grounds • Age 40 – 60 • Amenorrhoea • Hot flushes • Other causes of amenorrhoea excluded • In fact, women drift in and out of a state of ovarian failure, often over a period of 5 – 10 years... • And this is why measures of FSH and E2 are unreliable

  4. Menopausal Problems • The effects of oestrogen deficiency • Hot flushes • Genital tract atrophy • Accelerated bone mineral loss • Changed fat distribution • Skin, hair and dentition effects • ?Acceleration of atherosclerosis • ?Cognitive and mood changes • ?Reduced libido • The pros and cons of hormone replacement therapy (HRT) • Premature menopause • Postmenopausal bleeding • The effect of Tamoxifen on the Endometrium

  5. Hot Flushes (or Flashes) • Sensation of heat with sweating and palpitations • Can be documented by measuring skin temperature • Last 2 – 30 minutes • Frequency quite variable • May effect just the face and head or the whole body • Night sweats and insomnia the worst aspect • Occur in 85% of women • But only 15% so severe as to demand treatment • Tend to decrease with time • But can persist for years in a few women • Known triggers include: • Heat • Emotion • Alcohol, Caffeine, Smoking • Spicy foods • Correlate in time with GnRH release but exact mechanism unknown

  6. Management of Hot Flushes • Education • Cultural expectations seem important • Non pharmacological • Avoid known triggers • Exercise no benefit on RCT • Meditation/Relaxation of benefit in 1:2 RCT’s • Acupuncture, homeopathy, Vitamin E, Magnetic devices not effective • Pharmacological • ERT & HRT highly effective on RCT • Tibilone • SSRI and SNRI (Selective Serotonin Re-uptake Inhibitors) • Clonidine • Gabapentin • Soy products and Phytoestrogens inconclusive • Black cohosh effective in 66% women but safety for long term use uncertain

  7. The HRT Debate • Background • From 1960 – 1990 a number of observational studies suggested that postmenopausal hormone use (HRT) reduced the risk of cardiovascular disease • Taken together with the burden of illness from osteoporosis in older women, HRT was widely prescribed prophylactically to prevent these two diseases • Vigorously supported by drug firms and many women who saw this as an “elixir of youth” • In 2002 the results of a large prospective RCT in the US examined the risks and benefits of HRT in postmenopausal women • It is called the Women’s Health Initiative (WHI) and it caused waves around the world

  8. The WHI Study • Recruited 64,500 women for study over 15 years with the aim to evaluate risks and benefits of a low fat diet, HRT and calcium supplements • One part of that study was STOPPED after 5.2 years because of an increased risk of breast cancer • There was also an increased risk of cardiovascular disease in this group • Thus negating the principal argument for prophylactic HRT • This RCT involved 16608 women aged 50-79 years with an intact uterus at baseline in 40 US centres over 1993-98 • Combined HRT (Equine oestrogen 0.625 mg plus Provera 2.5 mg) was compared to placebo • Outcomes studied included thromboembolism, stroke, heart attack, breast, uterine and colon cancer and hip fracture • Results were published as risk ratios (95% confidence limits) and as absolute risk per 10,000 women

  9. The WHI Study Results - 1 • Breast Cancer • RR = 1.26 (CI 1.00 – 1.59) • 8 more cases per 10,000 women years • Cardiovascular Disease • RR = 1.29 (CI 1.02 – 1.63) • 7 more cases per 10,000 women years • Stroke • RR = 1.41 (CI 1.07 – 1.85) • 7 more events per 10,000 women years • Pulmonary Embolus • RR = 2.13 (CI 1.39 – 3.25) • 8 more cases per 10,000 women years

  10. The WHI Study Results - 2 • Colorectal Cancer • RR = 0.63 (CI 0.43 – 0.92) • 6 fewer cases per 10,000 women years • Hip Fractures • RR = 0.66 (CI 0.45 – 0.98) • 4 fewer cases per 10,000 women years • Endometrial Cancer • RR = 0.83 (CI 0.47 – 1.47) • All Mortality RR = 0.98 (CI 0.82 – 1.18) • That is unchanged • The study did not evaluate any aspect of patient satisfaction or quality of life

  11. WHI Results - 2004 • Another arm of the study that involved 10, 739 women after hysterectomy who received oestrogen-only HRT. Published in 2004 • Confirmed an increased risk of stroke but not cardiovascular disease or thromboembolism • A reduced risk of hip fracture but no effect on colon cancer • A trend towards reduced risk of breast cancer! • This study found no effect from ERT on a number of measures of quality of life • Including cognitive functioning and dementia

  12. Sequelae to the WHI study • Many criticisms of the study made • Some are statistical • Some focus on “horse oestrogens” and the progestin used • All point to the fact that ORAL oestrogens have profound effects on the liver • Most point out that many of the participants were long past menopausal and “too old” to benefit • Efforts to produce a selective oestrogen analogue without breast effects resulted in... • “Evista” = Raloxifene • “Livial” = Tibilone • HRT use in Australia and the US fell by 40% • And the incidence of postmenopausal breast cancer fell by 7% • But nobody seriously argues that all women should take HRT forever

  13. Current Consensus Statements on HRT Use • Because the carcinogenic potential for HRT on the breast does not appear for at least 5 years... • Combined HRT for the relief of menopausal symptoms is appropriate for a woman with a uterus in the minimum doses and for the minimum period required • Continuing HRT beyond this is a matter for individuals & their doctors and proceeds on the basis of “informed consensus” • Patients at risk of thromboembolism should be treated with special care • Patients with a history of breast cancer are best treated with non-hormonal alternatives • There are better alternatives for the prevention and treatment of osteoporosis (Biphosphonates & Vitamin D) • Patients without a uterus can use oestrogen-only ERT with greater impunity

  14. Tips for Prescribing HRT • Do not use continuous combined preparations until age >55 years • Use sequential preparations and warn about withdrawal bleeding • These preparations are NOT contraceptive • And irregular bleeding is often due to spontaneous ovarian activity • Warn the patient about side effects including... • Mastalgia • PV bleeding • Dysphoria • Thrush • Non oral routes are preferred but expensive • Consider vaginal use of tablets that are not enteric coated • Remember the use of Mirena as a good method of progestin administration • Wean patients off HRT very slowly over weeks • Rebound hot flushes can be quite severe

  15. Cochrane on the Menopause • HRT for Hot Flushes • 24 trials, 3329 women studied • Oestrogen only (ERT) or oestrogen plus progestin (HRT) are highly effective in preventing hot flushes • Side effects include PV bleeding, mastalgia and dysphoria • Minimum Doses of Progestin with HRT required to avoid Endometrial Hyperplasia • 45 studies • All doses of ERT results in endometrial hyperplasia after 12m • Counteracted by not less than 1.0 mg Norethisterone or 1.5 mg Medroxyprogesterone daily • Alternatives to HRT for Women with Breast Cancer • 16 RCT’s of agent against placebo • Clonidine, SSRI, SNRI, Gabapentin and relaxation therapy all mildly effective

  16. Cochrane on the Menopause - 2 • HRT and ERT for Cognitive Function in Postmenopausal Women • 24 trials 10,114 women • Neither ERT nor HRT prevents cognitive impairment with age • After 1 year of ERT or 3 years of HRT the net effect is NEGATIVE i.e. Worse cognitive function • Exercise and Hot Flushes • No convincing effect • But one study found that exercise enhanced the ameliorating effects of soy products • Vaginal Oestrogen Use • 19 trials 4162 women • Creams, pessaries and tablets all highly successful in treating the symptoms of vaginal atrophy • But vaginal rings that release oestrogen are the best • 14trials examined safety and some showed evidence for vaginal bleeding, mastalgia, perineal pain and endometrial hyperplasia

  17. Cochrane on the Menopause -3 • HRT for Urinary Incontinence in Postmenopausal Women • 33 trials 19,313 women • Systematic oestrogen or oestrogen plus progestin makes urinary incontinence significantly WORSE • Local (PV) oestrogen has a mildly beneficial effect • Mostly by reducing urinary frequency

  18. Premature Menopause • Definition • Menopause before the age of 40 • 45 by some criteria • Diagnosis • Amenorrhoea with high FSH • Beware of resistant ovary syndrome... • A condition of great unpredictability • Causes • Chromosomal • Chemotherapy or Radiotherapy • Surgical • There is a familial component • May be auto immune • Smoking • Hysterectomy even with preservation of the ovaries

  19. Effect of Age & Menopause on Bone Mineral Densitometry in Women

  20. Management of Premature Menopause • Because of the association between bone mass, age of menopause and osteoporosis there is a general consensus that premature menopause requires treatment at least until the mid 50’s • Also required when symptomatic • If there is a uterus present then combined HRT in greater doses than the average is usually required • E2 by implant and a Mirena is a good option • Oestrogen only (ERT) required after hysterectomy • Management of patients who have oestrogen-dependent tumours or residual pelvic endometriosis poses real problems • Donor eggs are an option for infertility

  21. Postmenopausal Bleeding • Should be regarded as due to Ca of the endometrium until proven otherwise • In fact, only 1:10 is Ca endometrium an the rest are due to • Polyps • Atrophic “vaginitis” • Patient not truly menopausal • Administered hormones • Beware of the high risk patient • Obese, diabetic and often hypertensive • Infertility (role of PCO disorder controversial) • Unopposed oestrogen therapy or Tamoxifen • Late menopause • Ca of breast or colon etc. • Make sure that the bleeding is vaginal in origin – not bowel or bladder

  22. Management of Postmenopausal Bleeding • Examination during bleeding is desirable • To confirm the symptom & ascertain site • Take an endocervical smear for cytology • Ultrasound of the uterus has a role • Will exclude Ca endometrium with 95 – 98% sensitivity if an endometrial stripe of ≤ 4mm is seen • The commonest cause of endometrial widening is polyps • They are best delineated by saline utrasonography • Pipelle endometrial biopsy will diagnose up to 99% of Ca endometrium • But is often negative or nondiagnostic in cases of polyp • May require gentle cervical dilatation • Hysteroscopy & Biopsy is the gold standard • But may be omitted in selected cases • Can be done as an outpatient procedure • Vaginal oestrogen and observation for suspected atrophic vaginitis is an option

  23. Tamoxifen and the Endometrium • This drug is widely used after breast cancer surgery • But within 12m of use 75% of patients will have endometrial changes on ultrasound • These consist of microcystic change in the proximal endometrium and adjacent myometrium • Postmenopausal patients on Tamoxifen are at small risk of developing endometrial cancer • Risk is between 0.2 and 4% per year • And it will always present with PV bleeding • Routine ultrasound monitoring of the endometrium is not recommended • And ultrasound has a limited role in the investigation of these patients if they experience bleeding • Early recourse to hysteroscopy and biopsy is best • But Pipelle may also have role

More Related